open access
Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod
Affiliations- Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
- Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland
open access
Abstract
Among patients with multiple sclerosis, discontinuing highly effective disease-modifying treatments can potentially lead to severe disease recurrence, especially cessation of natalizumab and fingolimod. Similar to fingolimod, siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes. In the present case report, we describe a patient with MS who experienced substantial disease exacerbation after withdrawal from siponimod.
Abstract
Among patients with multiple sclerosis, discontinuing highly effective disease-modifying treatments can potentially lead to severe disease recurrence, especially cessation of natalizumab and fingolimod. Similar to fingolimod, siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes. In the present case report, we describe a patient with MS who experienced substantial disease exacerbation after withdrawal from siponimod.
Keywords
Multiple sclerosis, Siponimod, Withdrawal, Rebound, Fingolimod
About this articleTitle
Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod
Journal
Neurologia i Neurochirurgia Polska
Issue
Pages
98-101
Published online
2017-10-13
Page views
475
Article views/downloads
690
DOI
10.1016/j.pjnns.2017.10.001
Bibliographic record
Neurol Neurochir Pol 2018;52(1):98-101.
Keywords
Multiple sclerosis
Siponimod
Withdrawal
Rebound
Fingolimod
Authors
Tomasz Litwin
Łukasz Smoliński
Anna Członkowka
